Differences

This shows you the differences between two versions of the page.

--- natalie_dayneka [2022/04/19 20:51]
liam [Career]
+++ natalie_dayneka [2022/04/19 22:15] (current)
liam [Funding]
@@ Line 7: / Line 7: @@
 Dayneka has worked as a pharmacist in several locations including Churchill, Manitoba, Philadelphia, and at [[SickKids]] in Toronto, Ontario.((Children's Healthcare Canada. (2013, September 27). //Improving Adolescent Medication Adherence.// YouTube. https://web.archive.org/web/20220419175950/https://www.youtube.com/watch?v=OgsPiCH27fg))
-She has published research on behalf of the Department of Pharmaceutics, School of Pharmacy at the [[State University of New York]] and the [[Philadelphia College of Pharmacy and Science]].((Dayneka, N. L., Garg, V., & Jusko, W. J. (1993). //Comparison of four basic models of indirect pharmacodynamic responses.// Journal of Pharmacokinetics and Biopharmaceutics, 21(4), 457–478. https://doi.org/10.1007/bf01061691))
+She has published research on behalf of the Department of Pharmaceutics at the [[State University of New York]] School of Pharmacy and the [[Philadelphia College of Pharmacy and Science]].((Dayneka, N. L., Garg, V., & Jusko, W. J. (1993). //Comparison of four basic models of indirect pharmacodynamic responses.// Journal of Pharmacokinetics and Biopharmaceutics, 21(4), 457–478. https://doi.org/10.1007/bf01061691))
-Dayneka is a clinical specialist with the Pharmacy Department of the tertiary care pediatric teaching hospital [[Children's Hospital of Eastern Ontario]] (CHEO). She was a co-author of the online 2015 CHEO Antimicrobial Guidelines for Children which has been offered externally as a mobile application (APP) for pediatric practitioners across Canada.
+Dayneka is a clinical specialist with the Pharmacy Department of the tertiary care pediatric teaching hospital [[Children's Hospital of Eastern Ontario]] (CHEO).((//Natalie Dayneka - Clinical Specialist and.. - CHEO.// ZoomInfo. Retrieved April 19, 2022, from https://web.archive.org/web/20220419191517/https://www.zoominfo.com/p/Natalie-Dayneka/87864102)) She was a co-author of the online 2015 CHEO Antimicrobial Guidelines for Children which has been offered externally as a mobile application (APP) for pediatric practitioners across Canada.
-She has consulted on various federal committees and was a member of the Pharmacology and Therapeutics Committee for the [[First Nations and Inuit Health Programs Directorate]]. She also served on the [[Canadian Paediatric Society]]'s Drug Therapy and Hazardous Substances Committee. More recently, she served on the [[Ontario Quality Based Procedure Tonsillectomy Clinical Expert Advisory Group]].
+She has consulted on various federal committees and was a member of the Pharmacology and Therapeutics Committee for the [[First Nations and Inuit Health Programs Directorate]]. She also served on the [[Canadian Paediatric Society]]'s Drug Therapy and Hazardous Substances Committee. CPS receives funding through sponsorships by [[pharmaceutical_companies:Abbott]], [[pharmaceutical_companies:AstraZeneca]], [[Canadian Institutes for Health Research]], [[pharmaceutical_companies:Elvium Life Sciences]], [[pharmaceutical_companies:GlaxoSmithKline]], [[pharmaceutical_companies:Johnson & Johnson]], [[pharmaceutical_companies:Medexus Pharma]], [[pharmaceutical_companies:Merck]], [[pharmaceutical_companies:Pendopharm]], [[pharmaceutical_companies:Pfizer]], [[pharmaceutical_companies:Sanofi Genzyme]], and [[pharmaceutical_companies:UltraGenyx]].((Canadian Paediatric Society. //Thank our partners.// 98th Annual Conference | Canadian Paediatric Society. Retrieved April 19, 2022, from https://archive.ph/Sq1DQ))
-She has been very active with the [[Canadian Society of Hospital Pharmacists]] (CSHP) and was awarded the title of Fellow.
+More recently, she served on the Ontario Quality Based Procedure Tonsillectomy Clinical Expert Advisory Group.((//Paediatric Tonsillectomy with and without Adenoidectomy QBP Clinical Expert Advisory Group.// (2015, July). Wayback Machine; Provincial Council for Maternal and Child Health. https://web.archive.org/web/20210304094328/https://www.pcmch.on.ca/wp-content/uploads/2015/07/QBP_Tonsillectomy_Membership.pdf))
+==== Canadian Society of Hospital Pharmacists ====
+Dayneka is a Fellow of the [[Canadian Society of Hospital Pharmacists]] (CSHP).((//Annual Professional Practice Conference - Awards Program.// (2019, February 2). Wayback Machine; Canadian Society of Hospital Pharmacists. https://web.archive.org/web/20210812133311/https://cshp.ca/document/4143/Awards2019_Final_reduced.pdf)) The CSHP receives funding through sponsorships and foundation donations from [[pharmaceutical_companies:Accel Pharma]], [[pharmaceutical_companies:Amgen]], [[pharmaceutical_companies:Apotex]], [[pharmaceutical_companies:Astellas]], [[pharmaceutical_companies:AstraZeneca]], [[Canadian Pharmaceutical Distribution Network]], [[pharmaceutical_companies:Fresenius Kabi]], [[HealthPro]], [[[[pharmaceutical_companies:Janssen]], [[pharmaceutical_companies:Knight Therapeutics]], [[pharmaceutical_companies:LEO Pharma]], [[pharmaceutical_companies:Marcan Pharmaceuticals]], [[pharmaceutical_companies:Omega]], [[pharmaceutical_companies:Otsuka]], [[pharmaceutical_companies:Pfizer]], [[pharmaceutical_companies:Pharmascience]], [[pharmaceutical_companies:Sandoz]], [[pharmaceutical_companies:Sanofi]], [[pharmaceutical_companies:SteriMax]], [[pharmaceutical_companies:Teva]], and [[pharmaceutical_companies:Viatris]].((//2021 Donors to the CSHP Foundation by Giving Level.// Canadian Society of Hospital Pharmacists. Retrieved April 19, 2022, from https://archive.ph/u6NsN)) ((//2020 Donors to the CSHP Foundation by Giving Level.// Canadian Society of Hospital Pharmacists. Retrieved April 19, 2022, from https://archive.ph/IX7Ga)) ((//2019 Donors to the CSHP Foundation by Giving Level.// Canadian Society of Hospital Pharmacists. Retrieved April 19, 2022, from https://archive.ph/Aj6wg)) ((//2018 Donors to the CSHP Foundation by Giving Level.// Canadian Society of Hospital Pharmacists. Retrieved April 19, 2022, from https://archive.ph/ofnfV)) ((//2017 Donors.// Canadian Society of Hospital Pharmacists. Retrieved April 19, 2022, from https://archive.ph/OCDBC)) ((//2016 Donors.// Canadian Society of Hospital Pharmacists. Retrieved April 19, 2022, from https://archive.ph/uWyb4))
 ==== Canadian HIV/AIDS Pharmacists Network ====
 Dayneka has served as a member, Chair and Past Chair of the [[Canadian HIV and Viral Hepatitis Pharmacists Network|Canadian HIV/AIDS Pharmacists Network]] (CHAP) (now called the [[Canadian HIV and Viral Hepatitis Pharmacists Network]]),((//Network.// Canadian HIV/AIDS Pharmacists Network. Retrieved April 19, 2022, from https://web.archive.org/web/20220419182107/https://hivclinic.ca/chap/network.php)) ((Dayneka, N., Sheehan, N., Kelly, D., Lemire, B., Martel, D., Turcotte, I., Marquis, M.-P., Laroche, M., Therrien, R., Giguère, P., Yoong, D., Tseng, A., Robinson, L., Chan, S., Stuber, M., Hughes, C., Foisy, M., Kapler, J., Mah Ming, J., & Akagi, L. (2016). //Fall 2016 Newsletter.// The Canadian HIV/AIDS Pharmacists Network (CHAP). https://web.archive.org/web/20220419182634/https://hivclinic.ca/chap/downloads/newsletters/newsletter_2016_fall.pdf)) ((Hughes, C., & Meneilly, G. (2000). //Annual Meeting 2000 Minutes.// Canadian HIV/AIDS Pharmacists Network. https://web.archive.org/web/20220419183515/https://hivclinic.ca/chap/downloads/minutes/minutes_2000.pdf)) where she published research sponsored by [[pharmaceutical_companies:Merck]].((Taylor, S. A. N., Foisy, M. M., Tseng, A., Beardsall, A., Ostrop, N., Khaliq, Y., Shevchuk, Y., Chin, T., Gin, A., Dayneka, N., Slater, K., Meneilly, G., and Hughes, C. for the Canadian Collaborative HIV/AIDS Pharmacy Network. (2000). //The role of the pharmacist caring for people living with HIV/AIDS: A Canadian position paper.// Can J Hosp Pharm, 53(2), 92–103. https://web.archive.org/web/20220419181446/https://www.hivclinic.ca/chap/downloads/Role_of_the_pharmacist_CHAP_position_paper_CJHP00.pdf)) Additional sponsors of the network during her membership include [[pharmaceutical_companies:Abbott]],  [[pharmaceutical_companies:AbbVie]], [[pharmaceutical_companies:Boehringer Ingelheim]], [[pharmaceutical_companies:Bristol-Myers Squibb]], [[pharmaceutical_companies:Gilead Sciences]], [[pharmaceutical_companies:Janssen]], [[pharmaceutical_companies:Theratechnologies]], and [[pharmaceutical_companies:ViiV Healthcare]].((//CHAP Annual Meetings.// Canadian HIV and Viral Hepatitis Pharmacists Network. Retrieved April 19, 2022, from https://archive.ph/0lNW7)) The network itself is sponsored by the [[Toronto General Hospital]] HIV Clinic, which is funded through unrestricted grants by AbbVie, Gilead Sciences and ViiV Healthcare.((//Courage Lives Here.// Immunodeficiency Clinic. Retrieved April 19, 2022, from https://web.archive.org/web/20220419182422/https://hivclinic.ca/))
 ==== Public Health Agency of Canada ====
@@ Line 25: / Line 28: @@
 Dayneka formerly served on the [[National Advisory Committee on Immunization]] (NACI), including as chair of the Vaccine Safety Working Group.((Dayneka, N., Jensen, C., & Hildebrand, K. (2020). //Canadian Immunization Guide: “Anaphylaxis and other acute reactions following vaccination” chapter update.// Canada Communicable Disease Report, 46(1112), 384–386. https://doi.org/10.14745/ccdr.v46i1112a04))
+===== Research =====
+Dayneka has published research on [[H1N1]] [[influenza]] [[vaccines]].((SchulerCHEO, J. E., King, W. J., Dayneka, N. L., Rastelli, L., Marquis, E., Chad, Z., & Hui, C. (2011). //Administration of the adjuvanted pH1N1 vaccine in egg-allergic children at high risk for influenza A/H1N1 disease.// Canadian Journal of Public Health, 102(3), 196–199. https://doi.org/10.1007/bf03404895))
+==== Funding ====
+In 1993, Dayneka received research funding from the [[National Institute of General Medicine Services]] (NIGMS) under the [[National Institutes of Health]] (NIH).((Dayneka, N. L., Garg, V., & Jusko, W. J. (1993). //Comparison of four basic models of indirect pharmacodynamic responses.// Journal of Pharmacokinetics and Biopharmaceutics, 21(4), 457–478. https://doi.org/10.1007/bf01061691)) She disclosed engaging in consulting activities for [[pharmaceutical_companies:Gilead Sciences]] and [[pharmaceutical_companies:Janssen]].((Kreutzwiser, D., Sheehan, N., Dayneka, N., Lemire, B., Wong, A., Samson, L., & Brophy, J. (2016). //Therapeutic drug Monitoring Guided Raltegravir Dosing for Prevention of Vertical Transmission in a Premature Neonate Born to a Woman Living with Perinatally Acquired HIV.// Antiviral Therapy, 22(6), 545–549. https://doi.org/10.3851/imp3139)) Further research was funded by [[pharmaceutical_companies:AstraZeneca]], [[medical_technology_companies:Cook]], and [[pharmaceutical_companies:Covidien]].((Stewart, P., Dayneka, N., Grenier, S., Stewart, C., Beadow, L., Joseph, G., Mack, D., & Vaillancourt, R. (2009). //In Vitro Study of Esomeprazole Sachet Suspension Administered via Enteral Feeding Tubes.// The Canadian Journal of Hospital Pharmacy, 62(1). https://doi.org/10.4212/cjhp.v62i1.122))